[English]  [Pусский]  [中文]  
ctt-journal > Zagoskina 1 et al. (Abstract)

Zagoskina 1 et al. (Abstract)

Cellular Therapy and Transplantation (CTT), Vol. 3, No. 9
doi: 10.3205/ctt-2010-No9-abstract39
© The Authors. This abstract is provided under the following license: Creative Commons Attribution 3.0 Unported

Abstract accepted for "4th Raisa Gorbacheva Memorial Meeting on Hematopoietic Stem Cell Transplantation",
Saint Petersburg, Russia, September 18–20, 2010

Contribute a comment


Rituximab therapy of chronic lymphocytic leukemia patients in remission

Tamara P. Zagoskina, Olga V. Malykh, Ekaterina N. Zotina, Irina V. Grishina

FGI “Kirov Institute of Hematology and Blood Transfusion of FMBA of Russia”, Kirov, Russia

Correspondence: Tamara P. Zagoskina, FGI “Kirov Institute of Hematology and Blood Transfusion of FMBA of Russia”, 72, Krasnoarmeiskaya str., 610027, Kirov, Russia, E-mail: zagoskina@spam is badblood.kirov.ru


The application of the combination of rituximab with a fludarabine-containing chemotherapy regimen in recent years has significantly improved the results of overall and disease-free survival of patients with chronic lymphocytic leukemia (CLL).

Aim: To study the efficiency of maintenance with rituximab after induction chemotherapy or immuno-chemotherapy in CLL patients.

Materials and methods. The study included 213 patients in remission. The age of patients ranged from 34 to 76 years (median, 59 years). Remission was induced after a RFC program in 117 patients and FC in 96 patients. Complete remission (CR) was observed in 121 (57%) patients, and partial remission (PR) in 92 (43%). The patients were randomly assigned to either observation (133 patients) or supporting rituximab therapy in the form of 4 weekly injections (375 mg/m2) every 6 months over 2 years (60 patients).

Results. The patients treated with a RFC regimen with subsequent rituximab maintenance had a significantly lower frequency of relapse and death compared to the observation group (χ2=10.749, p=0.001 and χ2=5.877, p=0.015, respectively). Analyzing these indicators in patients treated with an FC regimen we also see the advantage of maintenance therapy in relation to the observation group (χ2=49.896, p=0.0001 and χ2=9.985, p=0.002, respectively). Comparative analysis of progression free survival (PFS) of CLL patients who received various regimens revealed a significant difference. Thus, in patients who completed the program followed by RFC and supporting rituximab therapy, the median PFS was achieved, while in patients without supporting rituximab therapy it was 42 months (p=0.009). The related indicators of patients receiving the combination of FC with further supporting rituximab therapy differed significantly: their median PFS was not achieved in contrast to patients in the monitoring group, whose PFS was 24 months (p=0.001). During the period of supporting rituximab therapy no additional toxicity was observed.

Conclusion. The results of our study confirm the role of rituximab therapy in CLL remission maintenance.

Keywords: chronic lymphocytic leukemia, supporting therapy, rituximab


<-- Previous abstract        Contents        Next abstract -->

Contribute a comment